Cellanyx is an emerging biotech company specializing in advanced diagnostic tests for cancer, particularly prostate cancer. The company leverages proprietary phenotypic appearance and dynamics biomarker tests, utilizing machine vision and AI-driven analysis of live single tumor cells. These tests aim to improve risk stratification and support shared clinical decision-making for solid tumors.

Cellanyx primarily serves healthcare providers, including hospitals and specialized cancer treatment centers, who require precise diagnostic tools to better understand tumor aggressiveness and tailor treatment plans accordingly. Operating in the biotech and healthcare diagnostics market, Cellanyx's business model revolves around developing and commercializing laboratory-developed tests (LDTs).

The company generates revenue by selling these diagnostic tests to healthcare institutions and through partnerships with other biotech firms. Cellanyx has published several clinical proof-of-concept studies and is preparing for prospective clinical trials to further validate its technology.

Keywords: AI-driven diagnostics, phenotypic tests, prostate cancer, tumor aggressiveness, risk stratification, clinical decision support, live single cell analysis, healthcare diagnostics, biotech, laboratory-developed tests.